MOTS-c and the exercise claim
The exercise and muscle paper measured naturally occurring MOTS-c in people and tested administered MOTS-c in mice. The performance findings belong to the mice. The human measurements don’t show that giving the peptide improves fitness.
The registered MOTS-c study concerns adults with prediabetes and extra weight. It plans to test insulin sensitivity, how well the body responds to insulin. The registry record had no results as of September 30, 2026; it describes a plan, not a finding.
The FDA’s MOTS-c review describes missing human and animal safety work. It also explains the agency’s concern about possible immune reactions to injected peptides, including clumps and impurities. It doesn’t supply a rate of side effects in people.
CJC-1295 and ipamorelin
The albumin-binding experiments in rats help explain the long-acting CJC-1295 form. Albumin is a blood protein that the added attachment binds to.
The small CJC-1295 studies in healthy adults measured growth hormone and IGF-1, a related growth factor. FDA says the human studies appear to have used DAC, but the exact form and salt weren’t clear. Higher levels don’t establish better sleep, muscle or recovery, and the studies didn’t test the ipamorelin pair.
The receptor interaction experiment used engineered cells to explore how hormone signals work together. It wasn’t a treatment trial of the combination.
The ipamorelin bowel-surgery trial tested a hospital use, given into a vein. It found no significant benefit on its main outcomes. That setting can’t answer questions about wellness injections under the skin.
The FDA reviews of CJC-1295 and ipamorelin cover their forms, human evidence and safety concerns. They discuss each substance separately. The ipamorelin review includes two deaths after cancer-surgery complications in the intravenous trial. FDA said it was unclear whether ipamorelin contributed, while still treating the deaths as a safety concern.
Sermorelin’s clinical past
The childhood growth study involved children with diagnosed growth hormone deficiency and had no comparison group. The clinical review describes childhood testing, treatment and older side-effect observations.
The short study in older men measured hormone changes. It doesn’t establish lasting health benefits.
The 2009 approval withdrawal and later Geref determination explain the former product’s history. Neither approves a current compounded preparation.
U.S. compounding records
The FDA’s compounding explanation separates compounded medicines from approved products. Its bulk-substance safety page, current as of April 22, 2026, lists withdrawn nominations and Category 2 entries. Withdrawal isn’t clearance. These U.S. sources don’t establish Australian access.